Fig. 4: Identification of subtype-specific genetic biomarkers for FOLFIRI plus cetuximab or bevacizumab. | Nature Communications

Fig. 4: Identification of subtype-specific genetic biomarkers for FOLFIRI plus cetuximab or bevacizumab.

From: The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

Fig. 4

Subtype-specific genetic biomarkers for OS of a cetuximab and b bevacizumab using hazard ratios including 95% confidence intervals (CI) derived from single Cox regression models. Subtypes are defined by either the primary tumour side, CMS or unstratified (reference model). Kaplan–Meier plots including 95% CIs, hazard ratios and raw p-values derived by Wald tests from the Cox regression models of subtype-specific genetic biomarkers for c ARFRP1 in CMS2, d KRAS in CMS4, e KRAS in CMS2 and f KRAS in CMS1 in either the cetuximab or bevacizumab treatment arm. A Source Data file is provided, which contains the source data for the figure panels and the sample sizes of the conducted statistical tests.

Back to article page